Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a next-generation small-molecule inhibitor that targets VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, demonstrating marked anti-angiogenic effects in cell-based assays (APExBIO). It exhibits rapid oral absorption, high plasma protein binding (93% in humans), and broad tissue distribution, including tumor and brain tissue (Chen & Feng 2019). Compared to sunitinib and sorafenib, Anlotinib (hydrochloride) offers superior inhibition of endothelial cell migration and tube formation. Preclinical safety studies report a high median lethal dose (LD₅₀ 1735.9 mg/kg, 14-day oral) and low organ/genetic toxicity. APExBIO supplies Anlotinib hydrochloride (SKU: C8688) for research use, supporting advanced angiogenesis and tumor signaling pathway studies.

Biological Rationale

Angiogenesis is a vital process in tumor growth and metastasis, regulated by tyrosine kinase signaling cascades involving the VEGF, PDGF, and FGF pathways. Dysregulation of these pathways is implicated in various cancers and resistance to conventional therapies (see foundational review). Multi-target tyrosine kinase inhibition is a validated strategy to disrupt tumor vascularization, impede nutrient supply to tumors, and inhibit metastatic spread. Anlotinib hydrochloride was developed to achieve broad-spectrum inhibition of angiogenic tyrosine kinases with high selectivity and minimal off-target toxicity. Its pronounced efficacy in blocking endothelial cell migration and capillary-like tube formation in vitro underscores its utility for dissecting angiogenic mechanisms in cancer research (see comparative analysis).

Mechanism of Action of Anlotinib (hydrochloride)

• Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor (TKI) acting primarily on VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (APExBIO).
• The compound competes with ATP at the kinase domain, blocking autophosphorylation and subsequent activation of downstream signaling, including the ERK pathway.
• This inhibition translates into suppressed VEGF/PDGF-BB/FGF-2-induced endothelial cell migration and tube formation, key steps in angiogenesis.
• Anlotinib also inhibits other kinases, such as c-Kit and Met, but with lower potency compared to its primary targets (Chen & Feng 2019).
• Unlike non-selective TKIs, Anlotinib demonstrates minimal off-target activity, reducing systemic toxicity in preclinical models.

Evidence & Benchmarks

• Anlotinib hydrochloride inhibits VEGFR2, PDGFRβ, and FGFR1 in kinase assays with IC₅₀ values of 5.6 ± 1.2 nM, 8.7 ± 3.4 nM, and 11.7 ± 4.1 nM, respectively (APExBIO).
• In endothelial cell assays (EA.hy 926), Anlotinib suppresses VEGF/PDGF-BB/FGF-2-induced migration and tube formation in a concentration-dependent manner (mechanism dossier).
• Compared to sunitinib, sorafenib, and nintedanib, Anlotinib demonstrates superior inhibition of angiogenic signaling in both in vitro and xenograft models (Chen & Feng 2019).
• Oral bioavailability in rats (28%–58%) and dogs (41%–77%) suggests favorable pharmacokinetics for in vivo studies (APExBIO).
• High plasma protein binding (93% in humans) and extensive tissue distribution, including accumulation in lung, liver, kidney, heart, tumor, and brain tissues (APExBIO).
• Minimal unchanged drug excreted; mainly metabolized by CYP3A to hydroxylated and dealkylated metabolites.
• Median lethal dose (LD₅₀): 1735.9 mg/kg (14-day oral, rat), indicating low systemic toxicity (APExBIO).
• In a clinical case, Anlotinib treatment reduced metastatic lymph nodes in intra-abdominal desmoplastic small round cell tumor (IADSRCT) with manageable side effects (Chen & Feng 2019).

Applications, Limits & Misconceptions

Anlotinib hydrochloride is used for research in tumor angiogenesis inhibition, cell migration assays, and evaluation of tyrosine kinase signaling pathways. It offers advantages in models requiring high sensitivity to VEGFR2, PDGFRβ, and FGFR1 blockade. It is not approved for diagnostic or clinical use, and its use is confined to scientific research in vitro or in vivo animal models. For an expanded protocol and troubleshooting guide, see this workflow resource, which this article updates with recent pharmacokinetic and selectivity data.

Common Pitfalls or Misconceptions

• Not for Clinical/Diagnostic Use: Anlotinib hydrochloride from APExBIO is sold strictly for research applications, not for therapeutic or diagnostic procedures.
• Target Spectrum: While potent for VEGFR2, PDGFRβ, and FGFR1, Anlotinib is significantly less active against unrelated kinases and does not inhibit all angiogenic pathways.
• Off-Label Cell Lines: Efficacy data is robust in endothelial and selected tumor cell lines; activity in non-vascular or non-tumor models may not extrapolate.
• Species-Specific Pharmacokinetics: Oral bioavailability and tissue distribution may vary across species; dosing optimization is essential for translational work.
• Resistance Mechanisms: Like other TKIs, chronic exposure may lead to acquired resistance; combinatorial approaches should be considered for long-term studies.

Workflow Integration & Parameters

• Storage: Store Anlotinib hydrochloride at -20°C; protect from moisture and light for stability.
• Solubility: Soluble in DMSO; prepare fresh aliquots for each experiment.
• Assay Models: Use in endothelial cell migration and tube formation assays, typically with EA.hy 926 or HUVEC cells.
• Dosing Range: Effective concentrations typically range from 1 nM to 1 μM, with IC₅₀ values in the low nanomolar range for primary targets.
• Controls: Include sunitinib, sorafenib, or nintedanib as reference comparators for benchmarking effects.
• Pharmacokinetics: For in vivo studies, consider species-specific absorption, distribution, metabolism, and excretion data.
• Data Interpretation: Monitor for off-target effects and validate target engagement using phosphorylation or reporter assays.

For detailed protocols and troubleshooting, refer to the C8688 kit documentation and this comparative review, which this article extends by including recent case-report evidence and updated selectivity data.

Conclusion & Outlook

Anlotinib hydrochloride (APExBIO) represents a benchmark compound for dissecting multi-target angiogenic signaling in cancer research. Its high target specificity, favorable pharmacokinetics, and validated anti-angiogenic effects in preclinical and case-report settings make it a preferred tool for advanced tumor biology models. Future research may clarify its combinatorial value with immunotherapies and address resistance mechanisms. For further reading, see this foundational summary, which is enhanced here by recent clinical and pharmacological insights.